Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral levonorgestrel Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

NCT04142762
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Zibotentan, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 6, 2026, 2:52 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Teen Vulnerability to Irritability: Brain and Estrogen Changes

NCT07544966
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Irritability
Interventions
Kurvelo, Placebo COC
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 16 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 6, 2026, 2:52 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

NCT07525791
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0662-0419, Oral contraceptive, Acetaminophen
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 6, 2026, 2:52 PM EDT
Completed No phase listed Observational

Hormonal Influences on Inflammatory Bowel Diseases

NCT05610527
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Contraception, Menstrual Problem
Interventions
Proposed study design and randomization scenarios, Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments, Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

NCT04018274
View directory record Official record
Conditions
Healthy
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 6, 2026, 2:52 PM EDT
Withdrawn Phase 2 Interventional

IUD and Norethindrone Acetate for Treatment of Endometriosis

NCT04948489
View directory record Official record
Conditions
Endometriosis
Interventions
norethindrone acetate (NETA), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 24 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
View directory record Official record
Conditions
Healthy
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Not applicable Interventional Results available

Managing Temporomandibular Disorder (TMD) Symptoms

NCT00237042
View directory record Official record
Conditions
Temporomandibular Joint Disorders
Interventions
Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2011 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

NCT01181479
View directory record Official record
Conditions
Contraception
Interventions
AG200-15 (cycles 1-13), Lessina crossover to AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
17 Years to 40 Years · Female only
Enrollment
1,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
80
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

NCT03984825
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Portia
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

NCT06657105
View directory record Official record
Conditions
Healthy Participants
Interventions
EE/LNG, Baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive

NCT00196326
View directory record Official record
Conditions
Contraception
Interventions
DR-1011
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
2,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
55
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Obesity, Oral Contraception, and Ovarian Suppression

NCT00827632
View directory record Official record
Conditions
Ovarian Suppression
Interventions
Low dose formulation, High dose formulation
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

NCT01291004
View directory record Official record
Conditions
Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size, Oral Contraceptive
Interventions
Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 6, 2026, 2:52 PM EDT
Completed No phase listed Observational Results available

Same Day Oral EC and Implant Initiation

NCT04678817
View directory record Official record
Conditions
Contraception
Interventions
Etonogestrel contraceptive implant with oral levonorgestrel, Levonorgestrel intrauterine device, Copper T380A intrauterine device
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196313
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, Placebo tablet
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
Up to 17 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
13
States / cities
Denver, Colorado • Decatur, Georgia • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

NCT02824224
View directory record Official record
Conditions
Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions
Tamoxifen, Placebo (for Tamoxifen)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 6, 2026, 2:52 PM EDT
Withdrawn Phase 3 Interventional

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

NCT06904274
View directory record Official record
Conditions
Endometrial Hyperplasia
Interventions
BAY865028, Medroxyprogesterone acetate
Combination Product · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hormonal Birth Control and the Risk of Acquiring HIV

NCT00006324
View directory record Official record
Conditions
HIV Infections
Interventions
Ethinyl estradiol/levonorgestrel, Medroxyprogesterone acetate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
16 Years to 35 Years · Female only
Enrollment
6,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Sep 6, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 6, 2026, 2:52 PM EDT